Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey

Drug Metabolism and Disposition

Volumn 35, Issue 8, 2007, Pages 1275-1284

  Nishimura, Tomohiro ^a   Amano, Nobuyuki ^b   Kubo, Yoshiyuki ^a   Ono, Midori ^b   Kato, Yukio ^a   Fujita, Hisashi ^b   Kimura, Yoshiaki ^b   Tsuji, Akira ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; DRUG METABOLITE; MIDAZOLAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APICAL MEMBRANE; ARTICLE; BASEMENT MEMBRANE; CELL SURFACE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; FIRST PASS EFFECT; INTESTINE ABSORPTION; INTESTINE MUCOSA; LIVER METABOLISM; MALE; MATHEMATICAL MODEL; MONKEY; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; SPECIES COMPARISON;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOTTING, WESTERN; CYTOCHROME P-450 CYP3A; DOGS; DUODENUM; GABA MODULATORS; ILEUM; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; JEJUNUM; MACACA FASCICULARIS; MALE; MIDAZOLAM; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

MACACA FASCICULARIS; RATTUS;

EID: 34547209778     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013037     Document Type: Article

References (38)

1. Aiba T, Yoshinaga M, Ishida K, Takehara Y, and Hashimoto Y (2005) Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol Pharm Bull 28:311-315.
2. Benet LZ and Cummins CL (2001) The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 50 (Suppl 1):S3-S11.
3. Benet LZ, Cummins CL, and Wu CY (2004) Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Chiou WL and Buehler PW (2002) Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res (N Y) 19:868-874.
6. Cummins CL, Jacobsen W, and Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036-1045.
7. Cummins CL, Jacobsen W, Christians U, and Benet LZ (2004) CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther 308:143-155.
8. Daniel H (2004) Molecular and integrative physiology of intestinal peptide transport. Annu Rev Physiol 66:361-384.
9. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (N Y) 10:1093-1095.
10. Fisher JM, Wrighton SA, Calamia JC, Shen DD, Kunze KL, and Thummel KE (1999) Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding. J Pharmacol Exp Ther 289:1143-1150.
11. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
12. Hashizume T, Mise M, Matsumoto S, Terauchi Y, Fujii T, Imaoka S, Funae Y, Kamataki T, and Miyazaki H (2001) A novel cytochrome P450 enzyme responsible for the metabolism of ebastine in monkey small intestine. Drug Metab Dispos 29:798-805.
13. Higashikawa F, Murakami T, Kaneda T, Kato A, and Takano M (1999) Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51:67-72.
14. Johnson BM, Charman WN, and Porter CJ (2003) Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab Dispos 31:1151-1160.
15. Kanazu T, Yamaguchi Y, Okamura N, Baba T, and Koike M (2004) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402.
16. Katsura T and Inui K (2003) Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab Pharmacokinet 18:1-15.
17. Kolars JC, Schmiedlin-Ren P, Dobbins III WO, Schuetz J, Wrighton SA, and Watkins PB (1992a) Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102:1186-1198.
18. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, and Watkins PB (1992b) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878.
19. Lau CE, Ma F, Wang Y, and Smith C (1996) Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. Psychopharmacology (Berl) 126:241-248.
20. Li LY, Amidon GL, Kim JS, Heimbach T, Kesisoglou F, Topliss JT, and Fleisher D (2002) Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther 301:586-593.
21. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
22. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
23. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, and Serabjit-Singh CS (2001) Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
24. Sai Y and Tsuji A (2004) Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today 9:712-720.
25. Sakuda S, Akabane T, and Teramura T (2006) Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 36:331-340.
26. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, and Yamazaki H (1997) Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401-408.
27. Sietsema WK (1989) The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27:179-211.
28. Tam D, Sun H, Pang KS (2003) Influence of P-glycoprotein, transfer clearances, and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. Drug Metab Dispos 31:1214-1226.
29. Tamai I, Saheki A, Saitoh R, Sai Y, Yamada I, and Tsuji A (1997) Nonlinear intestinal absorption of 5-hydroxytryptamine receptor antagonist caused by absorptive and secretory transporters. J Pharmacol Exp Ther 283:108-115.
30. Terao T, Hisanaga E, Sai Y, Tamai I, and Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083-1089.
31. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
32. Tolle-Sander S, Rautio J, Wring S, Polli JW, and Polli JE (2003) Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res (N Y) 20:757-764.
33. Tsuji A and Tamai I (1996) Carrier-mediated intestinal transport of drugs. Pharm Res (N Y) 13:963-977.
34. Ward KW, Nagilla R, and Jolivette LJ (2005) Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human. Xenobiotica 35:191-210.
35. Ward KW and Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611.
36. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
37. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (N Y) 22:11-23.
38. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, and Kaminsky LS (1999) Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804-809.